ReviewEuropean cardiology2023
Ablation as First-line Therapy for Atrial Fibrillation.
Review in European cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Preprocedural systemic immune-inflammation index predicts atrial fibrillation recurrence after catheter ablation: A systematic review and meta-analysis.Biomolecules & biomedicine · 2026Pooled it
- Colchicine initiated before radiofrequency-induced injury attenuates left atrial inflammation, fibrosis, and susceptibility to atrial fibrillation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026Article
- Pre-ablation Weight Loss Via Metabolic Bariatric Surgery is Associated with Lower In-hospital Complications in Patients with Atrial Fibrillation/flutter.Obesity surgery · 2026Article
- Atrial Cardiomyopathy.Maedica · 2026Article
- Determinants of symptom relief and quality of life improvement after atrial fibrillation ablation.European heart journal. Quality of care & clinical outcomes · 2026Article
- Application of Artificial Intelligence in the Early Detection and Management of Atrial Fibrillation: State-of-the-art Review.European cardiology · 2026Review
- Machine Learning and Arrhythmia: Advances in Atrial Fibrillation Detection and Management.Current atherosclerosis reports · 2025Review
- A case of Dressler's syndrome after pulsed field ablation for atrial fibrillation.HeartRhythm case reports · 2025Article
- Direct-to-catheter ablation versus second line catheter ablation for persistent atrial fibrillation: Effect on arrhythmia recurrence, AF burden, early left atrium remodeling and quality of life.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2025Article
- SHDB-AF: a Japanese Holter ECG database of atrial fibrillation.Scientific data · 2025Article
- Cardioembolic Stroke: Past Advancements, Current Challenges, and Future Directions.International journal of molecular sciences · 2024Review
- How to assess cryoballoon ablation-related adverse events.Journal of arrhythmia · 2023Article
- Decoding the evidence: A synopsis of indications and evidence for catheter ablation in atrial fibrillation (Review).Medicine internationalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AF is a chronic and progressive heart rhythm disorder characterised by exacerbations and remissions. Contemporary guidelines recommend antiarrhythmic drugs (AADs) as the initial therapy for the maintenance of sinus rhythm. However, these medications have modest efficacy and are associated with significant adverse effects. Several recent trials have evaluated catheter ablation as an initial therapy for AF, demonstrating that cryoballoon catheter ablation significantly improves arrhythmia outcomes (e.g. atrial tachyarrhythmia recurrence and arrhythmia burden), produces clinically meaningful improvements in patient-reported outcomes (e.g. symptoms and quality of life), and significantly decreases healthcare resource usage (e.g. hospitalisation), without increasing the risk of serious adverse events. Moreover, in contrast to antiarrhythmic drugs, catheter ablation appears to be disease-modifying, significantly reducing the progression of disease. These findings are relevant to patients, providers, and healthcare systems, helping inform the initial choice of rhythm-control therapy in patients with treatment-naïve AF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.